DEA Order to Show Cause

A DEA Order to Show Cause (OSC) is the administrative proceeding the Drug Enforcement Administration uses to revoke, suspend, or refuse to renew a DEA registration under 21 USC 824. The OSC names the grounds (typically a public-interest determination under 21 USC 824(a)(4) plus specified statutory violations), gives the registrant 30 days to request a hearing, and proceeds to an administrative hearing before a DEA Administrative Law Judge. Revocation ends the registrant's ability to dispense, prescribe, or distribute controlled substances.

How a DEA Order to Show Cause works

The OSC issues from DEA Headquarters after a Diversion Investigator's case package, often built over months or years of inspection findings, inventory reconciliation, and pattern review. The registrant has 30 days from service to request a hearing under 21 CFR 1316.47; failure to request a hearing is treated as a waiver and DEA proceeds to a default revocation. After hearing request, the matter is assigned to a DEA Administrative Law Judge.

The hearing follows the procedural rules in 21 CFR Part 1316. DEA presents the case in chief, the registrant cross-examines and presents the defense, and the ALJ issues a recommended decision to the DEA Administrator. The Administrator's final order is appealable to a U.S. Court of Appeals. In parallel, DEA may seek an Immediate Suspension Order (ISO) under 21 USC 824(d) where DEA determines an imminent danger to public health and safety, suspending the registration immediately pending the OSC proceeding. Federal district court is available to challenge an ISO under 21 USC 824(d)(2).

When a DEA Order to Show Cause applies

An OSC applies to any DEA registrant: pharmacies, physicians, dentists, nurse practitioners, hospitals, distributors, manufacturers, and analytical laboratories. The most common triggers are diversion patterns (high opioid dispensing volumes, unusual prescriber concentrations, inventory shortages), corresponding-responsibility findings (failures of due diligence on individual prescriptions), Suspicious Order Monitoring (SOM) failures for distributors, and criminal indictment or conviction. Parallel federal criminal investigation often runs alongside the administrative OSC proceeding.

The registrant's exposure under a DEA Order to Show Cause

Revocation ends the registrant's controlled substance business. For pharmacies, that often means closing the doors because controlled substances are the keystone of the prescription mix. For physicians, that means losing the ability to prescribe controlled substances entirely. Parallel exposure includes state board action (the state license usually follows the DEA registration in some form), criminal investigation under 21 USC 841 for the underlying dispensing or prescribing patterns, and civil False Claims Act exposure where controlled substance dispensing supported Medicare or Medicaid claims. The defense framework focuses on the hearing record, expert testimony on the corresponding-responsibility analysis or diversion pattern, parallel criminal-track coordination, and federal district court challenge of any ISO.

Related terms

• Inventory reconciliation The audit technique that produces many of the variance findings supporting OSC matters.
• Subpoena The DEA Diversion Investigator's compulsory process that often precedes an OSC.
• Target letter The DOJ notification that may accompany an OSC where criminal investigation runs in parallel.
• OIG exclusion The collateral federal program consequence that may follow a controlled substance conviction.

See also

• Practice area
  DEA Defense

  The full DEA defense framework spanning inspections, Show Cause proceedings, ISOs, and parallel criminal coordination.

• Practice area
  DEA Inspections Defense

  Defense framework for DEA inspections that often produce the findings supporting later OSC proceedings.